Images List Premium Download Classic

Insulin Resistance

Insulin Resistance-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Modulation of agpat5 expression
Ionis Pharmaceuticals, Inc.
November 09, 2017 - N°20170321216

Provided herein are methods, compounds, and compositions for reducing expression of an agpat5 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological ...
Novel pentadienoyl piperidine derivative and use thereof
Snu R&db Foundation
November 09, 2017 - N°20170320825

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and ...
Compositions and methods for lipid metabolism disorder
Snu R&db Foundation
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Insulin Resistance Patent Pack
Download + patent application PDFs
Insulin Resistance Patent Applications
Download + Insulin Resistance-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Insulin Resistance-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Azelaic acid esters in the treatment of insulin resistance
New Frontier Labs, Llc
October 26, 2017 - N°20170304252

A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0. 1 mg/kg/day to about 10 mg/kg/day.
Rho associated kinase (rock) inhibitors and their use in treating disease
New Frontier Labs, Llc
October 19, 2017 - N°20170296617

The present disclosure describes peptide inhibitors of rho-associtated-kinase (rock) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the united states. An inhibitory polypeptide blocks rock1 activity in the presence of 1 mm atp. The binding epitope on rock1 was mapped using chemical cross-linking to the activation loop, a novel locus identifying ...
Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ...
New Frontier Labs, Llc
October 19, 2017 - N°20170296539

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in ...
Insulin Resistance Patent Pack
Download + patent application PDFs
Insulin Resistance Patent Applications
Download + Insulin Resistance-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Insulin Resistance-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Endorecherche, Inc.
October 12, 2017 - N°20170290847

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low dhea or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (dhea) and a selective estrogen receptor ...
Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
The Regents Of The University Of California
September 28, 2017 - N°20170275249

Compositions and methods are disclosed that relate to small molecule lipopeptidomimetic inhibitors of mammalian ghrelin o-acyl transferase (goat). Compounds of general formula (i) and substructures thereof, i. E., formulae (ii), (iia), (iia1), (iia2), (iib), (iib1), (iib2), (iic) and (iii), are shown to exhibit potent inhibition of the octanoylation of ghrelin peptide, where the resulting non-octanoylated (des-acyl) form of ghrelin lacks ...
Novel antagonists of the glucagon receptor
Metabasis Therapeutics, Inc.
September 28, 2017 - N°20170275246

The present invention provides for novel compounds of formula (i) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a ...
Compositions and methods for producing elevated and sustained ketosis
University Of South Florida
September 21, 2017 - N°20170266148

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period ...
Fgf-8 for use in treating diseases or disorders of energy homeostasis
Technische Universität München
September 14, 2017 - N°20170258874

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and ...
Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and method of ...
Wageningen Universiteit
September 07, 2017 - N°20170252421

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin ...
Insulin Resistance Patent Pack
Download + patent application PDFs
Insulin Resistance Patent Applications
Download + Insulin Resistance-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Insulin Resistance-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bioeffective krill oil compositions
Aker Biomarine Antarctic As
August 31, 2017 - N°20170246219

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical co2 or co2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill ...
Bioeffective krill oil compositions
Aker Biomarine Antarctic As
August 24, 2017 - N°20170240842

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical co2 or co2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill ...
Compositions and methods for regulating glucose homeostasis and insulin action
University Of Virginia Patent Foundation
August 24, 2017 - N°20170240563

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to bam15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent ...
Bioeffective krill oil compositions
Aker Biomarine Antarctic As
August 24, 2017 - N°20170239300

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical co2 or co2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill ...
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
Boehringer Ingelheim Vetmedica Gmbh
August 24, 2017 - N°20170239281

The present invention relates to combination of one or more sglt2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more ...
N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Universiteit Leiden
August 10, 2017 - N°20170226058

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency ...
Targeting micrornas for metabolic disorders
Eth Zurich
August 03, 2017 - N°20170218368

Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of mir-103. In certain embodiments, the methods comprise inhibiting ...
Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists
Vtv Therapeutics Llc
August 03, 2017 - N°20170216303

Phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same.
Loading